A Phase 2 interventional study of darunavir monotherapy in Maternal-fetal Infection Transmission, sponsored by ANRS, Emerging Infectious Diseases. Completed at 23 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by ANRS, Emerging Infectious Diseases · Phase 2, Interventional, and Treatment
The overall goal is to study the feasibility of darunavir/ritonavir (DRV/r) monotherapy as treatment simplification (switch) in pretreated pregnant women, associated with neonatal prophylaxis with nevirapine, constituting a PMTCT strategy without any Nucleoside Reverse Transcriptase Inhibitor (NRTIs) .
90 participants will be enrolled and switch to darunavir monotherapy early in pregnancy (before 16 weeks of amenorrhea) in order to reduce exposure to the antiretroviral nucleos(t)ide analogues. The study treatment during the pregnancy is: darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy This regimen will be started after checking the tolerance of DRV/r 600 mg/100 mg twice daily (recommended dosage for pregnancy in French national recommendations) to replace whatever prior antiretrovirals (ARVs) were used, while maintaining the NRTI backbone for 2 weeks. Woman already receiving a triple drug combination with DRV/r will proceed directly to treatment simplification. If clinical tolerance of DRV/r is satisfactory after 2 weeks, nucleos(t)ides will be stopped. In case of intolerance, the treatment will be determined by the investigator but follow-up of the patient will continue.
No zidovudine will be administered at delivery in case of virological control, according to French Guidelines (Morlat Report 2015).
After delivery, the choice of maternal antiretrovial therapy (ART) is left to the discretion of the clinician and patient.
The mothers are followed up monthly until delivery and the last visit is planes at W4-W6 postpartum. Virological efficacy and safety will be assessed monthly.
In neonates, the prophylactic treatment, nevirapine oral solution, will be administrated as soon as possible in the first 12 hours of life and then for 14 days, once a day at a daily dose of 15 mg for a birthweight ≥ 2.5 kg ; 10 mg for a birthweight ≥ 2 kg and \< 2.5 kg and 2 mg / kg for a birthweight \< 2 kg (WHO Guidelines 2013 - French Guidelines, "Morlat Report" 2015).
Clinical and virological monitoring will be performed at Day 3, Day 15 in case of hospitalization, M1, M3 and M6.
Statistical Methods The analysis of the primary endpoint is the proportion of virological success (VL \< 50 copies/mL at delivery among women remaining on DRV/r). All changes in antiretroviral therapy because of VL ≥ 50 copies/ml will be considered as failures. Women who change antiretroviral therapy for other reasons and/or when pregnancy outcome is before 22 weeks of amenorrhea and \< 500g (non-viable pregnancy according to WHO) will be removed from the denominator.
Analysis of treatment changes, tolerance for the mother and child and factors associated with virological failure will be done by estimating percentages (categorical variables), average and median (continuous variables) with their intervals 95% confidence, overall and compared between the groups with virological success or failure per protocol (primary endpoint) or by intention to treat (secondary endpoint). The evolution of the parameters measured in children at birth, at 1, 3, and 6, months will be explored using non-parametric curves and compared between groups by repeated data taking into account the nonlinearity developments.
No interim analysis is planned.
ANRS, Emerging Infectious Diseases is the lead sponsor of 212 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion criteria for the child :
Exclusion Criteria:
Exclusion criteria for the child:
Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
Drug: darunavir monotherapy
darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
Also known as: ritonavir
Success rate, defined by plasma viral load (PVL) <50 copies / mL near delivery with DRV/r monotherapy. Failure is defined as PVL > 50 copies / mL and/or change of antiretroviral therapy during pregnancy for PVL ≥ 50 copies / mL.
Time frame: At delivery (around 6 months after enrollment in the study).
Plasma viral load (PVL) <50 copies / mL at delivery, Intention-to-treat (ITT) analysis
Time frame: At delivery (around 6 months after enrollment in the study).
Incidence of treatment changes for inefficacy, defined as PVL≥ 50 copies / mL at 2 successive controls.
Time frame: Every month from Month1 up to the delivery.
Incidence of treatment changes for intolerance / toxicity.
Time frame: Every month from Month1 up to the delivery.
Incidence of treatment changes for other reasons.
Time frame: Every month from Month1 up to the delivery.
Factors associated with inefficacy (HIV-1 DNA). Inefficacy is defined as maternal plasma viral load > 50 copies/mL at delivery and/or change of antiretroviral therapy at any time from enrollment through delivery for plasma viral load > 50 copies/mL.
The following quantitative variables will be compared between women with inefficacy and those with virological success (plasma viral load \< 50 copies/mL under darunavir/ritonavir) : HIV-1 DNA (total HIV-DNA log10 copies/million peripheral blood mononuclear cells by the ANRS technique).
Time frame: Every month from Month1 up to the delivery.
Factors associated with inefficacy (lymphocytes T CD4+ count).
Inefficacy is defined as maternal plasma viral load \> 50 copies/mL at delivery and/or change of antiretroviral therapy at any time from enrollment through delivery for plasma viral load \> 50 copies/mL. The following quantitative variables will be compared between women with inefficacy and those with virological success (plasma viral load \< 50 copies/mL under darunavir/ritonavir) : CD4+ lymphocyte count/microL.
Time frame: Every month from Month1 up to the delivery.
Factors associated with inefficacy (CD4 nadir). Inefficacy is defined as maternal plasma viral load > 50 copies/mL at delivery and/or change of antiretroviral therapy at any time from enrollment through delivery for plasma viral load > 50 copies/mL.
The following quantitative variables will be compared between women with inefficacy and those with virological success (plasma viral load \< 50 copies/mL under darunavir/ritonavir) : CD4+ lymphocyte/microL nadir.
Time frame: Every month from Month1 up to the delivery.
Factors associated with inefficacy (duration of undetectable plasma viral load before pregnancy).
Inefficacy is defined as maternal plasma viral load \> 50 copies/mL at delivery and/or change of antiretroviral therapy at any time from enrollment through delivery for plasma viral load \> 50 copies/mL. The following quantitative variables will be compared between women with inefficacy and those with virological success (plasma viral load \< 50 copies/mL under darunavir/ritonavir) : duration of undetectable plasma viral load before pregnancy (months).
Time frame: Every month from Month1 up to the delivery.
Adverse pregnancy outcomes (preterm birth)
preterm birth : \< 37 weeks gestational age from last menstrual period)
Time frame: At delivery
Adverse pregnancy outcomes (fetal loss)
Fetal loss defined as all stillbirths and spontaneous abortions before 22 weeks gestation
Time frame: Every month from Month1 up to the delivery.
Adverse pregnancy outcomes (low birth weight)
low birth weight \< 3d percentile adjusted for gestational age and sex
Time frame: At delivery
Adverse pregnancy outcomes (low Apgar : < 7 at 5 minutes)
Time frame: At delivery
Adverse pregnancy outcomes (congenital malformations)
Malformations according to the European Surveillance of Congenital Anomalies (EUROCAT) classification)
Time frame: At delivery
Tolerance in children (hematological examinations).
Hemoglobin, red blood cell count, white blood cell counts and differentials and platelet counts /microL, and mean corpuscular volume in fL
Time frame: At delivery, Day 3, 15, Month1, 3 and 6
Tolerance in children (biochemical examinations).
AST and ALT, total bilirubin, lipase, sodium, potassium, urea, creatinine, calcium, phosphorus, lactates
Time frame: At delivery, Day 3, 15, Month1, 3 and 6
Interruption rate of postnatal nevirapine (NVP) within 2 weeks of life and patterns;
Time frame: Day 3, Day15
Any case of mother to child transmission would be considered a serious adverse event (SAE) and analyzed immediately.
Time frame: Day 3, Month1, Month 3 and Month 6.
Plan to share: Undecided
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ANRS, Emerging Infectious Diseases